» Articles » PMID: 38961521

Successful Utilization of Clozapine for a Patient with Treatment-resistant Schizophrenia After Recurrent Violent Behavior

Overview
Specialties Neurology
Pharmacology
Date 2024 Jul 4
PMID 38961521
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In patients with schizophrenia, violent behavior is a clinically important factor that prevents their discharge. Clozapine is an effective antipsychotic medication for treatment-resistant schizophrenia, and its usefulness for aggressive behavior has also been suggested.

Case Presentation: We present the case of a 38-year-old male patient diagnosed with schizophrenia who was successfully treated with clozapine after recurrent violent behavior. He was diagnosed with schizophrenia during his adolescence. He was hospitalized for treatment in his teens, but his hallucinations and delusions persisted even after discharge. In his 30s, he became noticeably emotionally unstable, and despite being treated for an adequate period with sufficient doses of several antipsychotics, his symptoms did not improve. This led to repeated hospitalizations triggered by violent behavior toward his parents and siblings within the home. During his fourth hospitalization, clozapine was initiated due to multiple incidents of violence toward nursing staff secondary to hallucinations and delusions. As the dose of clozapine was gradually increased with therapeutic drug monitoring, the patient's hostility, uncooperativeness, and suspiciousness markedly improved, and his aggressive behavior disappeared. He was discharged to a facility on day 194 after starting clozapine and has continued outpatient visits.

Conclusion: Clozapine was suggested to be effective for aggressive behavior in patients with treatment-resistant schizophrenia and should be actively considered. In such cases, regular measurement of blood concentration is useful for adjusting the dosage of clozapine.

Citing Articles

Successful utilization of clozapine for a patient with treatment-resistant schizophrenia after recurrent violent behavior.

Shinohara R, Oshima T, Otsubo T, Ariga K, Ono T, Muneoka K Neuropsychopharmacol Rep. 2024; 44(3):599-603.

PMID: 38961521 PMC: 11544433. DOI: 10.1002/npr2.12462.

References
1.
Volavka J, Citrome L . Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull. 2011; 37(5):921-9. PMC: 3160235. DOI: 10.1093/schbul/sbr041. View

2.
Schoretsanitis G, Kane J, Ruan C, Spina E, Hiemke C, De Leon J . A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol. 2019; 12(7):603-621. DOI: 10.1080/17512433.2019.1617695. View

3.
Shinohara R, Oshima T, Otsubo T, Ariga K, Ono T, Muneoka K . Successful utilization of clozapine for a patient with treatment-resistant schizophrenia after recurrent violent behavior. Neuropsychopharmacol Rep. 2024; 44(3):599-603. PMC: 11544433. DOI: 10.1002/npr2.12462. View

4.
Stark A, Scott J . A review of the use of clozapine levels to guide treatment and determine cause of death. Aust N Z J Psychiatry. 2012; 46(9):816-25. DOI: 10.1177/0004867412438871. View

5.
Kay S, Wolkenfeld F, Murrill L . Profiles of aggression among psychiatric patients. I. Nature and prevalence. J Nerv Ment Dis. 1988; 176(9):539-46. DOI: 10.1097/00005053-198809000-00007. View